Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 155

Similar articles for PubMed (Select 19001341)

1.

Pleomorphic lobular carcinoma of the breast: four long-term responders to trastuzumab--coincidence or hint?

Mahtani RL, Vogel CL.

J Clin Oncol. 2008 Dec 10;26(35):5823-4. doi: 10.1200/JCO.2008.19.8226. Epub 2008 Nov 10. No abstract available.

2.

Stability of HER2-positive status in breast carcinoma: a comparison between primary and paired metastatic tumors with regard to the possible impact of intervening trastuzumab treatment.

Xiao C, Gong Y, Han EY, Gonzalez-Angulo AM, Sneige N.

Ann Oncol. 2011 Jul;22(7):1547-53. doi: 10.1093/annonc/mdq623. Epub 2011 Jan 14.

3.

Herceptin (trastuzumab): adjuvant and neoadjuvant trials.

Yaal-Hahoshen N, Safra T.

Isr Med Assoc J. 2006 Jun;8(6):416-21. Review. No abstract available.

4.

Recent trends of HER-2 examination and a new strategy of trastuzumab therapy for primary and metastatic breast cancer.

Kurosumi M.

Breast Cancer. 2009;16(4):283. doi: 10.1007/s12282-009-0168-y. No abstract available.

PMID:
19756922
5.

Trastuzumab in breast cancer.

Banna GL, Santoro A.

N Engl J Med. 2006 Feb 9;354(6):640-4; author reply 640-4. No abstract available.

PMID:
16470951
6.

Isolated tumor cells in breast cancer.

Sonke GS, Linn SC.

N Engl J Med. 2009 Nov 12;361(20):1995; author reply 1995-6. No abstract available.

PMID:
19911470
7.

Trastuzumab after primary treatment for early stage HER2-positive breast cancer reduces recurrence.

Dent R, Clemons M.

Cancer Treat Rev. 2006 Apr;32(2):144-8. Epub 2006 Mar 6. No abstract available.

PMID:
16517084
8.

Trastuzumab-treated advanced breast cancer patients and brain metastases: just a little alert.

Torresi U.

Ann Oncol. 2008 Jan;19(1):191. doi: 10.1093/annonc/mdm530. No abstract available.

9.

[Trastuzumab (Herceptin) in the adjuvant treatment of HER-2-positive early breast cancer].

Láng I, Hitre E.

Magy Onkol. 2006;50(4):293-302. Epub 2007 Jan 10. Hungarian.

10.

Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy.

Burstein HJ, Winer EP.

J Clin Oncol. 2009 Dec 1;27(34):5671-3. doi: 10.1200/JCO.2009.24.2222. Epub 2009 Nov 2. No abstract available.

11.

Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.

Untch M, Fasching PA, Konecny GE, Hasmüller S, Lebeau A, Kreienberg R, Camara O, Müller V, du Bois A, Kühn T, Stickeler E, Harbeck N, Höss C, Kahlert S, Beck T, Fett W, Mehta KM, von Minckwitz G, Loibl S.

J Clin Oncol. 2011 Sep 1;29(25):3351-7. doi: 10.1200/JCO.2010.31.4930. Epub 2011 Jul 25.

12.

Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy.

Ladoire S, Arnould L, Mignot G, Coudert B, Rébé C, Chalmin F, Vincent J, Bruchard M, Chauffert B, Martin F, Fumoleau P, Ghiringhelli F.

Breast Cancer Res Treat. 2011 Jan;125(1):65-72. doi: 10.1007/s10549-010-0831-1. Epub 2010 Mar 13.

PMID:
20229175
13.

[Herceptin (trastuzumab)].

Yamashiro H, Toi M.

Gan To Kagaku Ryoho. 2007 Aug;34(8):1173-6. Review. Japanese.

PMID:
17687197
14.

Neoadjuvant trastuzumab for breast cancer. Better to stick with proven treatments.

[No authors listed]

Prescrire Int. 2013 Feb;22(135):39. Review.

PMID:
23444499
15.

Pathologic tumor response of invasive lobular carcinoma to neo-adjuvant chemotherapy.

Joh JE, Esposito NN, Kiluk JV, Laronga C, Khakpour N, Soliman H, Catherine Lee M.

Breast J. 2012 Nov-Dec;18(6):569-74. doi: 10.1111/tbj.12006. Epub 2012 Oct 4.

PMID:
23034096
16.
17.

[Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].

Mallmann P.

Internist (Berl). 2006 Nov;47(11):1183-5. German. No abstract available.

PMID:
17048017
18.

Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer.

Isakoff SJ, Baselga J.

J Clin Oncol. 2011 Feb 1;29(4):351-4. doi: 10.1200/JCO.2010.31.6679. Epub 2010 Dec 20. No abstract available.

19.

Microinvasive lobular carcinoma of the breast.

Howat AJ, Armour A, Ellis IO.

Histopathology. 2000 Nov;37(5):477-8. No abstract available.

PMID:
11119139
20.

Spotlight on trastuzumab as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.

Garnock-Jones KP, Keating GM, Scott LJ.

BioDrugs. 2010 Jun;24(3):207-9. doi: 10.2165/11204680-000000000-00000. No abstract available.

PMID:
20462285
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk